Monoclonal antibodies face longer development times

04/7/2011 | FierceBiotech

Monoclonal antibodies, or mAbs, now take longer to develop and get approval in the U.S. because of the complexity of disease targets and largely unmet need for life-threatening conditions, among other reasons, according to a report by Lisa Natanson, a Deloitte Recap analyst. Despite this scenario, mAb developers are likely to see continued growth given the drugs' higher success rates when it comes to clinical trials and approvals, compared with large- and small-molecule drugs, Natanson said.

View Full Article in:

FierceBiotech

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT